Antiviral prophylaxis and isolation for the control of pandemic influenza

International Journal of Environmental Research and Public Health

Volumn 11, Issue 8, 2014, Pages 7690-7712

  Zhang, Qingxia ^a   Wang, Dingcheng ^a  

^a UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Antiviral prophylaxis; Isolation; Mathematical modeling; Pandemic influenza

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

DRUG; INFLUENZA; NUMERICAL MODEL; STRATEGIC APPROACH; VACCINE;

ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; DISEASE DURATION; DISEASE TRANSMISSION; DRUG EFFICACY; EPIDEMIC; HUMAN; INFECTION PREVENTION; INFLUENZA VIRUS A H5N1; INTERVENTION STUDY; MATHEMATICAL MODEL; PANDEMIC INFLUENZA; SEASONAL VARIATION; SYMPTOMATOLOGY; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS STRAIN; ANTIBIOTIC PROPHYLAXIS; ECONOMICS; INFLUENZA, HUMAN; ORGANIZATION AND MANAGEMENT; PANDEMICS; PATIENT CARE; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; THEORETICAL MODEL; TRANSMISSION; VIROLOGY;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN; MODELS, THEORETICAL; PANDEMICS; PATIENT ISOLATION; POST-EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS;

EID: 84905646590     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph110807690     Document Type: Article

References (28)

1. Li, K.S.; Guan, Y.; Wang, J. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in Eastern Asia. Nature 2004, 430, 209-213.
2. Beigel, J.H.; Farrar, J.; Han, A.M. Avian influenza a (H5N1) infection in humans. N. Engl. J. Med. 2005, 353, 1374-1385.
3. Arinaminpathy, N.; McLean, A.R. Antiviral treatment for the control of pandemic influenza: Some logistical constraints. J. R. Soc. Interface 2008, 5, 545-553.
4. McCaw, J.M.; McVernon, J. Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic. Math. Biosci. 2007, 209, 336-360.
5. Fedson, D.S. Pandemic influenza and the global vaccine supply. Clin. Infect. Dis. 2003, 36, 1552-1561.
6. Webby, R.J.; Webster, R.G. Are we ready for pandemic influenza? Science 2003, 302, 1519-1522.
7. Barnes, B.; Glass, K.; Becker, N.G. The role of health care workers and antiviral drugs in the control of pandemic influenza. Math. Biosci. 2007, 209, 403-416.
8. Longini, I.M., Jr.; Nizam, A.; Xu, S.; Ungchusak, K.; Hanshaoworakul, W.; Cummings, D.A.T.; Halloran, M.E. Containing pandemic influenza at the source. Science 2005, 309, 1083-1087.
9. Black, A.J.; House, T.; Keeling, M.J.; Ross, J.V. Epidemiological consequences of household-based antiviral prophylaxis for pandemic influenza. J. R. Soc. Interface 2013, 10, doi: 10.1098/risf.2012.1019.
10. Cheng, M.H. Flu, what flu. Lancet Infect. Dis. 2005, 5, doi:10.1016/S1473-3099(05)70290-5.
11. Lett, D. Feds to stockpile antivirals as pandemic "speed bump". Can. Med. Assoc. J. 2005, 172, 1167-1167.
12. Esveld, M. Influenza as an issue on the agenda of policymakers and government representatives. What can we do? What do we need? Vaccine 2006, 24, 6793-6795.
13. Harrod, M.E.; Emery, S.; Dwyer, D.E. Antivirals in the management of an influenza pandemic. Med. J. Aust. 2006, 185, S58-S61.
14. Becker, N.G.; Wang, D. Can Antiviral Drugs Contain Pandemic Influenza Transmission? PLoS One 2011, 6, doi:10.1371/journal.pone.0017764.
15. Lee, S.; Chowell, G.; Castillo-Chávez, C. Optimal control for pandemic influenza: The role of limited antiviral treatment and isolation. J. Theor. Biol. 2010, 265, 136-150.
16. Yan, X.; Zou, Y. Optimal and sub-optimal quarantine and isolation control in SARS epidemics. Math. Comput. Model. 2008, 47, 235-245.
17. Merler, S.; Ajelli, M.; Rizzo, C. Age-prioritized use of antivirals during an influenza pandemic. BMC Infect. Dis. 2009, 9, doi:117.10.1186/1471-2334-9-117.
18. Arino, J.; Brauer, F.; van den Driessche, P.; Watmough, J.; Wu, J. Simple models for containment of a pandemic. J. R. Soc. Interface 2006, 3, 453-457.
19. Ferguson, N.M.; Cummings, D.A.T.; Cauchemez, S.; Fraser, C.; Riley, S.; Meeyai, A.; Iamsirithaworn, S.; Burke, D.S. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005, 437, 209-214.
20. Gumel, A.B.; Ruan, S.; Day, T.; Watmough, J.; Brauer, F.; van den Driessche, P.; Gabrielson, D.; Bowman, C.; Alexander, M.E.; Ardal, S.; et al. Modelling strategies for controlling SARS outbreaks. Proc. R. Soc. Lond. B 2004, 271, 2223-2232.
21. Ferguson, N.M.; Cummings, D.A.T.; Fraser, C.; Cajka, J.C.; Cooley, P.C.; Burke, D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442, 448-452.
22. Pellis, L.; Ball, F.; Trapman, P. Reproduction numbers for epidemic models with households and other social structures. I. Definition and calculation of R0. Math. Biosci. 2012, 235, 85-97.
23. Towers, S.; Vogt Geisse, K.; Zheng, Y.; Feng, Z. Antiviral treatment for pandemic influenza: Assessing potential repercussions using a seasonally forced SIR model. J. Theor. Biol. 2011, 289, 259-268.
24. Becker, N.G.; Wang, D.; Clements, M. Type and quantity of data needed for an early estimate of transmissibility when an infectious disease emerges. Eurosurveillance 2010, 15, pii:19603.
25. Van den Driessche, P.; Watmough, J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. J. Math. Biol. 2002, 180, 29-48.
26. Ludkovski, M.; Niemi, J. Optimal dynamic policies for influenza management. Stat. Commun. Infect. Dis. 2010, 2, doi:10.2202/1948-4690.1020.
27. Yarmand, H. Cost-Effectiveness Analysis of Vaccination and Self-Isolation in Case of H1N1. Master's Thesis, North Carolina State University, Raleigh, NC, USA, 4 April 2010.
28. Hayward, A.C.; Fragaszy, E.B.; Bermingham, A.; Wang, L.; Copas, A.; Edmunds, W.J.; Ferguson, N.; Goonetilleke, N.; Harvey, G.; Kovar, J.; et al. Comparative community burden and severity of seasonal and pandemic influenza: Results of the Flu Watch cohort study. Lancet Respir. Med. 2014, 2014, doi:10.1016/S2213-2600(14)70034-70037.